Behavioral and psychological symptoms in dementia (BPSD) are often overlooked due to the main focus of treating or preventing cognitive decline symptoms. Almost two-thirds of patients with dementia will develop some type of noncognitive symptoms that include symptoms such as wandering, agitation, sexually inappropriate behaviors, physical and verbal aggression, uncooperativeness, and “sun-downing.” Psychological symptoms include depression, anxiety, delusions, hallucinations, and suspiciousness/paranoia. Worsening of these symptoms can lead to caregiver burden and is one of the major reasons for patients with dementia to be institutionalized. A major drawback of treating these symptoms pharmacologically is that the response rate is low with the current available therapies such as antipsychotics, anxiolytics, and antidepressants. In addition, all of these therapeutic classes have drawbacks due to side effect profiles. This article provides an overview of the current recommendations for pharmacological approaches for the treatment of behavioral and psychological symptoms of dementia.
Get full access to this article
View all access options for this article.
References
1.
1. American Psychiatric Association Workgroup on Alzheimer’s Disease and Related Disorders. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life . Am J Psychiatry. 1997;154(suppl.): 1-39 .
2.
2. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia . J Am Geriatr Soc. 1990;38: 553-563 .
3.
3. Schneider LS, Sobin PB. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer’s disease and other dementia . Psychopharmacol Bull. 1992;28: 71-79 .
4.
4. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique . Am J Geriatr Psychiatry. 2001;9: 361-381 .
5.
5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidenced-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology . Neurology. 2001;56: 1154-1166 .
6.
6. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update . JAMA. 1997;278: 1186-1190 .
7.
7. Alexopoulos GS, Katz IR, Reynolds CF, et al. Pharmacotherapy of depressive disorders in older patients . Postgrad Med Spec Rep. 2001;10: 1-88 .
8.
8. Datto CJ, Oslin DW, Streim JE, et al. Pharmacologic treatment of depression in nursing home residents: a mental health services perspective . J Geriatr Psychiatry Neurol. 2002;15: 141-146 .
9.
9. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings . J Clin Psychiatry. 1990;51(suppl.): 41-47 .
10.
10. Streim JE, Oslin DW, Katz IR, et al. Drug treatment of depression in frail elderly nursing home residents . Am J Geriatr Psychiatry. 2000;8: 150-159 .
11.
11. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease . Am J Geriatr Psychiatry. 2000;8: 66-74 .
12.
12. Beck CK, Vogelpohl TS, Rasin JH, et al. Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents . Nurs Res. 2002;51: 219-228 .
13.
13. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial . J Clin Psychiatry. 1999;60: 107-115 .
14.
14. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders . Clin Ther. 1984;6: 546-559 .
15.
15. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia . Neurology. 1999;53: 946-955 .
16.
16. Clark WS, Street JS, Feldman PD, et al. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s . Dis J Clin Psychiatry. 2001;62: 34-40 .
17.
17. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities . Arch Gen Psychiatry. 2000; 57: 968-976 .
18.
18. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients . Am J Psychiatry. 1982;139: 1170-1174 .
19.
19. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience . Int Psychogeriatr. 1997;9: 65-68 .
20.
20. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients . Am J Psychiatry. 1990;147: 1640-1645 .
21.
21. Tariot PN. Ismail MS. Use of quetiapine in elderly patients . Jour of Clinl Psych.2003; 63 Suppl 13: 21-26 .
22.
22. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine . South Med J. 1975;68: 719-724 .
23.
23. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients . J Am Geriatr Soc. 1998;46: 620-625 .
24.
24. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders . Br J Psychiatry. 1990;157: 894-901 .
25.
25. Ramadan FH, Naughton BJ, Bassanelli AG. Treatment of verbal agitation with a selective serotonin reuptake inhibitor . JGeriatr Psychiatry Neurol. 2000;13: 56-59 .
26.
26. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia . Am J Psychiatry. 1998;155: 54-61 .
27.
27. Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia . J Neuropsychiatry Clin Neurosci. 1995;7: 314-319 .
28.
28. Marshall LL, Miller SW. Divalproex sodium for the behavioral manifestations of Alzheimer’s disease . Consult Pharm. 2001;16: 758-766 .
29.
29. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting . J Am Geriatr Soc. 2001;49: 1590-1599 .
30.
30. Cantillon M, Brunswick R, Molina D, et al. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease . Am J Geriatr Psychiatry. 1996;4: 263-267 .
31.
31. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer’s disease . Clin Neuropharm. 2002;25: 313-317 .
32.
32. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia . Int J Clin Pract2002; 127: 20-36 .
33.
33. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature . J Am Geriatr Soc. 2003;51: 1305-1317 .
